In conclusion, our findings suggest that oral CAIs, especially acetazolamide, may be more effective than anti-VEGF therapy in improving visual function and restoring retinal anatomy in patients with RP-CME within 6 months. The gene discussed is VEGFA; the disease is retinitis pigmentosa 1.